S'abonner

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial - 30/06/26

Doi : 10.1016/S1470-2045(26)00178-6 
Giulio Francolini, MD a, ⁎ , Vanessa Di Cataldo, MD a, Saverio Caini, MD PhD b, Pietro Garlatti, MD a, Michele Aquilano, MD a, Niccolò Bertini, MD a, Alessio Bruni, MD PhD c, Gianluca Ingrosso, MD PhD d, Rolando M D’Angelillo, ProfMD PhD e, Luca Tagliaferri, MD PhD f, g, Barbara A Jereczek-Fossa, ProfMD PhD h, i, Matteo Augugliaro, MD j, Luca Triggiani, MD PhD k, Silvana Parisi, MD PhD l, Lorenzo Masieri, ProfMD PhD m, n, Riccardo Campi, MD PhD m, n, Richard K Valicenti, ProfMD MA o, Gabriele Simontacchi, MD a, Daniela Greto, MD a, Pierluigi Bonomo, MD a, Mauro Loi, MD a, Chad Tang, MD p, Lorenzo Livi, ProfMD PhD a
on behalf of the

ARTO Working Group †

  Members listed in the Supplementary Material
Giulia Marvaso, Filippo Alongi, Andrea Gaetano Allegra, Andrea Lancia, Fabio Arcidiacono, Annamaria Vinciguerra, Ciro Franzese, Giorgia Timon, Cinzia Iotti, Monica Mangoni, Isacco Desideri, Icro Meattini, Carlotta Becherini, Raffaela Doro, Laura Masi

a Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy 
b Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy 
c Radiation Oncology Unit, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy 
d Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy 
e Radiation Oncology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy 
f UOC Degenze di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy 
g Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy 
h Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy 
i Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy 
j Unit of Radiotherapy, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy 
k Department of Radiation Oncology, Università degli studi di Brescia, Brescia, Italy 
l Radiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy 
m Unit of Urology and Renal Transplantation Oncology Department, Careggi University Hospital, Florence, Italy 
n Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy 
o Department of Radiation Oncology, UC Davis, Davis, CA, USA 
p Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 

* Correspondence to: Giulio Francolini, Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence 50141, Italy Radiation Oncology Unit Oncology Department Azienda Ospedaliero Universitaria Careggi Florence 50141 Italy

Summary

Background

The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer. The aim of this analysis is to explore the long-term impact of MDT on overall survival.

Methods

ARTO was a multicentre, phase 2, randomised trial conducted in 16 academic and community centres across Italy. All patients included were aged 18 years or older and had a diagnosis of prostate adenocarcinoma with metastatic castrate-resistant prostate cancer, no more than three metastatic sites, and no previous systemic therapy for metastatic castrate-resistant prostate cancer status. Patients were randomly assigned (1:1, using random permuted blocks; stratified by treating centre, Eastern Cooperative Oncology Group performance status, and number of metastases) in an open-label design to androgen deprivation therapy plus oral abiraterone acetate 1000 mg daily with or without SBRT to all sites of metastatic disease (one to five fractions providing a biologically effective dose ≥100 Gy). The primary endpoint was 6-month biochemical response (PSA decrease of ≥50% compared with baseline) and has been reported previously. After meeting its primary endpoint, the power calculation was updated post-hoc to assess overall survival, finalised before data unmasking. We present an unplanned long-term follow-up focusing on overall survival. All analyses were performed on an intention-to-treat basis. The trial is registered on ClinicalTrials.gov ( NCT03449719 ) and is now closed.

Findings

Between Jan 2, 2019, and Sept 7, 2022, 157 patients were randomly assigned to the control (n=82) and experimental (n=75) groups. No data about race or ethnicity were collected. After a median follow up of 53 months (IQR 43–60), median overall survival was 50 months (95% CI 36–not reached [NR]) in the control group versus NR (55–NR) in the experimental group (HR 0·55, 95% CI 0·33–0·92, p=0·021). Most common grade 3–4 adverse events recorded were infectious complications (five in the control group vs zero in the experimental group) and cardiovascular disorders (three in the control group vs three in the experimental group). One treatment-related death occurred in the control group due to myocardial failure.

Interpretation

The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone.

Funding

Fondazione Radioterapia Oncologica.

Le texte complet de cet article est disponible en PDF.

Plan


© 2026  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 27 - N° 7

P. 830-838 - juillet 2026 Retour au numéro
Article précédent Article précédent
  • Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer
  • Orit Kaidar-Person, Caroline G Weltens, Catherine Fortpied, Luc J E E Scheijmans, Carine Y Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Mariacarla Valli, Max Peters, Femke van der Leij, Sofia Rivera, Nicola Weidner, Desirée H J G van den Bongard, Claudia Linsenmeier, Roxolyana Abdah-Bortnyak, Shaymaa Hosni, Eveline Koiter, Antoine M Engelen, Adinda Baten, Lydia Champezou, Alain Fourquet, Harry G M M Bartelink, Henk Struikmans, Philip M P Poortmans, EORTC Radiation Oncology and Breast Cancer Groups
| Article suivant Article suivant
  • Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
  • James P Buteau, Daniel Moon, Michael T Fahey, Matthew J Roberts, Narjess Ayati, Nathan Papa, Declan G Murphy, Veeru Kasivisvanathan, Haryana M Dhillon, Yang T Du, Philip Dundee, Jessica Foudoulis, David Hennes, Anthony C Hutton, Jordan Idiare, Greg Jack, Sheshang Kamath, Sophie N Lee, Su-Faye Lee, Sze Ting Lee, Scott Leslie, Sidney M Levy, Emma Link, Catherine Mitchell, Joshua J Morigi, Andrew Nguyen, Joanna Olphert, Manish I Patel, David A Pattison, Adam Pearce, Marlon Perera, Ruban Thanigasalam, Alice Thomson, John Yaxley, James Thompson, Michael S Hofman, Louise Emmett, PRIMARY2 Trial Investigators, Laura Adams, Tim J Akhurst, Omar Alghazo, Ramin Alipour, Narjess Ayati, Aries Balino, Ashley Baring, Salvatore Berlangieri, Madison Bills, Emma Boehm, Raef Boktor, Neeraja Bollampally, Caitlin Burt, James P Buteau, Emma Callegari, Anthony Cardin, Yee Chan, David C Chen, Tina Chen, Karla Cullen, Richard De Abreu Lourenco, Katrina Devitt, Nattakorn Dhiantravan, Haryana M Dhillon, Juliana Di Iulio, Yang T Du, Philip Dundee, Renu Eapen, Louise Emmett, David Ende, Michael T Fahey, Dulash Fernando, Jessica Foudoulis, Roslyn J Francis, Mark Frydenberg, Geetha Guduguntla, Gaurav Ghosh, Jeremy P Grummet, Simon Harley, David Hennes, Adam Hickey, Bao Ho, Michael S Hofman, Emily Hong, Anthony C Hutton, Jordan Idiare, Greg Jack, Kerry E Jewell, Nikeith John, Sheshang Kamath, Raghava K Kashyap, Veeru Kasivisvanathan, Sabina Kesuma, Umar Khan, Grace Kong, Natalia Kovaleva, Eddie Lau, Nathan Lawrentschuk, Dominic Lee, Jonathan Lee, Su-Faye Lee, Sze Ting Lee, Sophie N Lee, Scott Leslie, Sidney M Levy, Sherrington Li, William Lindeman, Karen Lindsay, Emma Link, Aoife McVey, Catherine Mitchell, Kate Moodie, Daniel Moon, Joshua J Morigi, Declan G Murphy, Ben Namdarian, Ghazala Naureen, Alexander Nesbitt, Andrew Nguyen, Gaia Ninatti, Monica O’Neill, Jonathan O’Brien, Joanna Olphert, Nathan Papa, Leeanne Pasanen, Manish Patel, David A Pattison, Adam Pearce, Marlon Perera, Elisa Perry, Sruit Pillai, Aurora Poon, Weranja Ranasinghe, Aravind S Ravi Kumar, Matthew J Roberts, Javad Saghebi, Stephen Schlicht, Andrew M Scott, Clare Senko, Shekib Shahbaz, Jeremy Shapiro, Shikha Sharma, Gaurav Sharma, Gemma Sheehan-Dare, Edward Shen, Dinesh Sivaratnam, Ross Smith, Stephen Stuckey, Jo-Lynn Tan, Andrew Tauro, Ruban Thanigasalam, James Thompson, Alice Thomson, Jehan Titus, Leyna Tran, Christer W Valeriano, Sytse Van Beek, Daniel Valenzuela, Michela Vermeulen, Jess Watson, Shraddha Weir, David Wetherell, Aaron Jun Ning Wong, Keith Wong, Kelvin Yap, John Yaxley, Alex Zheng

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.